Skip to content
For laboratory research use only · Not for human or veterinary use · Qualified buyers only
Peptides

What Is PT-141? Cyclic Melanocortin-Receptor Agonist Identity and Documentation

A research-use identity note on PT-141 (bremelanotide): cyclic melanocortin-receptor agonist design, attributed published findings, and lot documentation.

What Is PT-141? Cyclic Melanocortin-Receptor Agonist Identity and Documentation

PT-141, also known as bremelanotide, is a cyclic melanocortin-receptor agonist used in receptor-pharmacology and neuroscience research. The original overview of this page asks three questions: cyclic peptide design, melanocortin-receptor research context, and identity, purity, and stereochemical considerations for the lot on the bench.

Editorial review: 17 November 2026. Prepared by Velnacor Research Desk for research-use communication only. Published findings below are attributed to the cited papers. They are not claims about a Velnacor lot and are not instructions for use in people or animals.

Cyclic design and receptor class

Molinoff and colleagues described PT-141 as a synthetic peptide analogue of α-melanocyte-stimulating hormone (α-MSH) and as an agonist at melanocortin receptors, including MC3R and MC4R, which are expressed primarily in the central nervous system (Molinoff et al., 2003). Diamond and colleagues later described PT-141 as a cyclic heptapeptide melanocortin analogue in a placebo-controlled pharmacokinetic and pharmacodynamic evaluation (Diamond et al., 2004). Those identity statements belong in the file: a cyclic melanocortin analogue is not a linear α-MSH fragment, and it is not a GHRH or GHSR analogue.

Stereochemistry and cyclization should be visible on the quotation, the label, and the report. A family name such as “melanocortin peptide” is not a specification. Neighboring catalog names, including other melanocortin analogues if they appear, should be listed as separate rows.

Because PT-141 is a cyclic analogue, a useful identity file records the cyclic form, the sequence as written on the report, and any stereochemical descriptors the laboratory actually used. Linear α-MSH, other melanocortin fragments, and a cyclic heptapeptide named PT-141 or bremelanotide are not interchangeable specifications. If a secondary article uses only a brand or synonym, the purchase file should still match the research name and the current-lot documents.

Published receptor-pharmacology observations — and their limits

Molinoff and colleagues reported that administration of PT-141 to rats and nonhuman primates resulted in penile erections, that systemic administration to rats increased c-Fos immunoreactivity in hypothalamic neurons, and that administration in the human study populations they described was associated with an increase in erectile activity (Molinoff et al., 2003). Diamond and colleagues reported that, in healthy men and in men with erectile dysfunction in a double-blind, placebo-controlled design, an erectile response measured by RigiScan was statistically significant versus placebo at the doses they studied, and they also reported pharmacokinetic parameters and common adverse events in those sessions (Diamond et al., 2004).

Those papers are published pharmacology and early clinical-research findings. They are cited here only as attributed results in the models and study populations described by the authors. They are not a protocol, they do not provide administration or dosing guidance, and they do not describe a current catalog lot. This page does not recommend personal or clinical use.

Identity, purity, and documentation

A useful quality review still separates sequence and cyclic form, purity, content, and lot matching. The name used on the brief — PT-141, bremelanotide, or the exact catalog SKU — should agree with the report and the label. What Is a Peptide COA?, How to Read a Peptide COA, HPLC vs Mass Spectrometry for Peptide Lot Review, Third-Party Peptide Testing, Explained, and lot traceability apply here as they do to other research peptides.

PT-141 appears in Velnacor’s research-material catalog (internal product record, slug pt141). There is not a standalone public landing page for every catalog name; use the product directory and the COA Library, then confirm the exact name, specification, and current-lot documents in the inquiry. For packing at supply scale, see wholesale peptides. A related comparison page, if needed later, should keep oxytocin or other catalog names on their own rows rather than collapsing them into this identity.

Selected published literature

  1. Molinoff PB, Shadiack AM, Earle D, Diamond LE, Quon CY. PT-141: a melanocortin agonist for the treatment of sexual dysfunction. Annals of the New York Academy of Sciences. 2003;994:96-102. doi:10.1111/j.1749-6632.2003.tb03167.x. PubMed 12851303. Cited as published pharmacology and early clinical-research observations, not as a use instruction.
  2. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141, a melanocortin receptor agonist, in healthy males and patients with mild-to-moderate erectile dysfunction. International Journal of Impotence Research. 2004;16(1):51-59. doi:10.1038/sj.ijir.3901139. PubMed 14963471. Cited as published clinical-research observations, not as a use instruction.

Sourcing notes for qualified buyers

Velnacor’s stated supply terms for qualified research and business buyers include: every batch is third-party tested; orders usually ship within 24 hours, subject to stock, documentation review, and destination; trial orders can start from one box of ten vials; parcels lost or damaged in transit are eligible for free reshipment or a refund; and neutral packaging is available when required. Velnacor operates its own production base and has a long-standing supply-chain business.

Those points describe documentation and fulfillment. They do not describe a laboratory or biological outcome. For an order-specific review, send the material name, specification, box quantity, and destination through the inquiry list.

Research-use notice. All Velnacor products are intended strictly for laboratory research use only. They are not drugs, supplements, or food, and are not intended to diagnose, treat, cure, or prevent any disease. Not for human or veterinary use. Purchasers must be qualified researchers. This article is educational content for laboratory and business readers. It does not provide dosing, reconstitution, administration, diagnostic, or treatment guidance.

My inquiry listNo products added yet0